A Pharmacokinetic and Tolerability Evaluation of Two Continuous Subcutaneous Infusion Systems Compared to an Oral Controlled-Release Morphine Pia Mikkelsen.

Slides:

Advertisements

Similar presentations

Using a Morphine Equivalence Metric to Quantify Opioid Consumption: Examining the Capacity to Provide Effective Treatment of Debilitating Pain at the Global,

Advertisements

Morphine Inhalation by Cancer Patients: A Comparison of Different Nebulization Techniques Using Pharmacokinetic, Spirometric, and Gasometric Parameters

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Steady-State Kinetics and Dynamics of Morphine in Cancer Patients

The Public Health Strategy for Palliative Care

Palliative Care in Norway: A National Public Health Model

The Concept of Quality of Life of Dying Persons in the Context of Health Care Anita L Stewart, PhD, Joan Teno, MD, MS, Donald L Patrick, PhD, MSPH, Joanne.

Use of Transcutaneous Electrical Nerve Stimulation in a Young Child with Pain from Open Perineal Lesions Sandra I Merkel, MS, RN, Howard B Gutstein,

The Impact of Chronic Pain on Life in the Household

Comparison of Tropisetron and Chlorpromazine Combinations in the Control of Nausea and Vomiting in Patients with Advanced Cancer Kyriaki Mystakidou,

Efficacy and Safety of a Once-Daily Morphine Formulation in Chronic, Moderate-to- Severe Osteoarthritis Pain Jacques R. Caldwell, MD, Ronald J. Rapoport,

Patricia Ann Repar, DMA, Steve Reid, MD, PhD

Treat the Pain Program Journal of Pain and Symptom Management

Hospice and Palliative Care Development in Africa: A Multi-Method Review of Services and Experiences David Clark, PhD, Michael Wright, PhD, Jennifer.

Opioid Metabolites Journal of Pain and Symptom Management

Clearance of Meperidine and Its Metabolite Normeperidine in Hemodialysis Patients With Chronic Noncancer Pain Che-Hao Hsu, MD, Tso-Chou Lin, MD, Chih-Cherng.

Eduardo Bruera, MD, Raul Sala, MD, Odette Spruyt, MD, J

Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative.

Jessica Penn Lendon, PhD, Sangeeta C. Ahluwalia, PhD, MPH, Anne M

Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain Marianne Silver, MS, David Blum, MD,

David M. Dosa, MD, MPH, David D

Victor van Berkel, MD, PhD

Parent Perceptions of Child Vulnerability Are Associated With Functioning and Health Care Use in Children With Chronic Pain Mark Connelly, PhD, Kelly.

David Clark, PhD, Michael Wright, PhD

Xerostomia in Patients with Advanced Cancer

Once-Weekly Transdermal Buprenorphine Application Results in Sustained and Consistent Steady-State Plasma Levels Ram P. Kapil, PhD, Alessandra Cipriano,

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

Kenneth A Follett, MD, PhD, Claus P Naumann, MD

Slovenia Journal of Pain and Symptom Management

Suresh K Joishy, MD, FACP, Declan Walsh, MSc, FACP

Paul A. Sloan, MD, Dwight E. Moulin, MD, FRCP(C), Helen Hays, MD

Evaluation of Methadone Absorption After Topical Administration to Hospice Patients Robert K. Sylvester, PharmD, Caroline Schauer, RN, John Thomas, MD,

The Role of Patients' Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane T. Hickok, MD, MPH, Joseph A. Roscoe,

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

One, Two, or Three? Constructs of the Brief Pain Inventory Among Patients With Non- Cancer Pain in the Outpatient Setting Kate L. Lapane, PhD, Brian J.

Pharmacokinetics of Phenobarbital in Microenema Via Macy Catheter Versus Suppository Y.W. Francis Lam, PharmD, FCCP, Ansom Lam, MD, Brad Macy, RN, BSN,

Antonio T. Fernando, MD, Nathan S. Consedine, PhD

Evaluation of the FICA Tool for Spiritual Assessment

Improving Access to Opioid Analgesics for Palliative Care in India

Changing M3G/M6G Ratios and Pharmacodynamics in a Cancer Patient During Long- Term Morphine Treatment Gertrud Andersen, MD, Lona L Christrup, PhD, Per.

Drug Infusors in Palliative Medicine

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients.

Barriers to Cancer Pain Relief

Efficacy of Analgesics in Chronic Pain

Pain and Policy Studies Group: Two Decades of Working to Address Regulatory Barriers to Improve Opioid Availability and Accessibility Around the World

Subcutaneous Administration of Cefepime

Evaluating the Quality of Dying and Death

A Double-Blind, Randomized, Crossover Comparison Between Single-Dose and Double-Dose Immediate-Release Oral Morphine at Bedtime in Cancer Patients Ola.

Carmen R. Green, MD, Laura Montague, BS, Tamera A. Hart-Johnson, MS

A Scale for Measuring Patient Perceptions of the Quality of End-of-Life Care and Satisfaction with Treatment Daniel P. Sulmasy, OFM, MD, PhD, Jessica.

Perceived Success in Addressing End-of-Life Care Needs of Low-Income Elders and Their Families: What Has Family Conflict Got to Do With It? Betty J.

Continuous Subcutaneous Administration of High-Dose Salmon Calcitonin in Bone Metastasis Kyriaki Mystakidou, MD, PhD, Sofia Befon, MD, Kostas Hondros,

A Preliminary Study of the Utility of the Brief Hospice Inventory

Providing Constant Analgesia with OROS® Hydromorphone

Physical Function in Patients with Cancer

Morphine Bioavailability from a Topical Gel Formulation in Volunteers

Life-Threatening Dextromethorphan Intoxication Associated with Interaction with Amitriptyline in a Poor CYP2D6 Metabolizer: A Single Case Re-Exposure.

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial Zbigniew Zylicz, MD, PhD, Malgorzata Krajnik, MD, Adriaan.

Steady-State Pharmacokinetic Comparison of a New, Extended-Release, Once-Daily Morphine Formulation, Avinza™, and a Twice-Daily Controlled-Release Morphine.

Longitudinal Documentation of Cancer Pain Management Outcomes

Multidimensional independent predictors of cancer-related fatigue

Economic Evaluation of the Fentanyl Transdermal System for the Treatment of Chronic Moderate to Severe Pain Deirdre M Neighbors, BA, Timothy J Bell,

Lisa C. Lindley, PhD, RN, Jennifer W. Mack, MD, MPH, Donald J

The bioavailability of morphine applied topically to cutaneous ulcers

Associations Between Physical Activity and Quality of Life in Cancer Patients Receiving Palliative Care: A Pilot Survey Sonya S. Lowe, MD, MSc, Sharon.

Nausea and Vomiting Remain a Significant Clinical Problem

Physical Activity Behaviors in Individuals with Multiple Sclerosis: Roles of Overall and Specific Symptoms, and Self-Efficacy Erin M. Snook, MS, Robert.

Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life Ariel Berger, MPH, Ellen Dukes, PhD, RN, Meredith.

Presentation transcript:

A Pharmacokinetic and Tolerability Evaluation of Two Continuous Subcutaneous Infusion Systems Compared to an Oral Controlled-Release Morphine Pia Mikkelsen Lynch, MD, Jackie Butler, PhD, Deanne Huerta, LVN, Izrail Tsals, PhD, Diana Davidson, BS, Sharon Hamm, PharmD, RPh Journal of Pain and Symptom Management Volume 19, Issue 5, Pages 348-356 (May 2000) DOI: 10.1016/S0885-3924(00)00130-5

Fig. 1 MEDIPAD drug delivery system Journal of Pain and Symptom Management 2000 19, 348-356DOI: (10.1016/S0885-3924(00)00130-5)

Fig. 2 Top: Mean morphine plasma concentration versus time for MEDIPAD vs. CADD-Micro. Bottom: Mean morphine plasma concentration versus time for MS Contin Journal of Pain and Symptom Management 2000 19, 348-356DOI: (10.1016/S0885-3924(00)00130-5)

Fig. 2 Top: Mean morphine plasma concentration versus time for MEDIPAD vs. CADD-Micro. Bottom: Mean morphine plasma concentration versus time for MS Contin Journal of Pain and Symptom Management 2000 19, 348-356DOI: (10.1016/S0885-3924(00)00130-5)

Fig. 3 Top: Mean morphine plasma concentration versus time showing standard error for the MEDIPAD and the CADD-Micro. Bottom: Mean morphine plasma concentration versus time showing standard error for MS Contin Journal of Pain and Symptom Management 2000 19, 348-356DOI: (10.1016/S0885-3924(00)00130-5)

Fig. 3 Top: Mean morphine plasma concentration versus time showing standard error for the MEDIPAD and the CADD-Micro. Bottom: Mean morphine plasma concentration versus time showing standard error for MS Contin Journal of Pain and Symptom Management 2000 19, 348-356DOI: (10.1016/S0885-3924(00)00130-5)